Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Rule 5635(C)(4)
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company specializing in innovative treatments for neurological diseases, has announced the grant of inducement awards to two new employees. The Compensation Committee of Longboard’s Board of Directors approved non-qualified stock options to…
DocGo Extends $4 Million 911 Basic Life Support Contract with Atlantic City
DocGo Inc. (Nasdaq: DCGO), a leader in technology-enabled mobile health services, has announced that its subsidiary, Exceptional Medical Transportation, has been granted a one-year, $4 million contract extension. This extension will see Exceptional Medical Transportation continue to provide 911 basic…
Agilent’s MAGE-A4 IHC 1F9 PharmDx Approved by FDA for New TCR T-Cell Therapy
Agilent Technologies Inc. (NYSE: A) has announced FDA approval for its MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to identify patients with synovial sarcoma who may qualify for TECELRA® (afamitresgene autoleucel, or afami-cel), a MAGE-A4-directed engineered TCR T-Cell…
VBI Vaccines Updates Restructuring Efforts
VBI Vaccines Inc. (Nasdaq: VBIV) has provided an update on its restructuring proceedings, initially announced on July 30, 2024. U.S. Chapter 15 Filing:On August 2, 2024, the U.S. Bankruptcy Court for the District of Delaware granted provisional relief under Chapter…
Owens & Minor Reports Q2 2024 Financial Results
Owens & Minor, Inc. (NYSE: OMI) Announces Second Quarter Financial Results for 2024 Owens & Minor, Inc. (NYSE: OMI) has released its financial results for the second quarter ending June 30, 2024. Key Highlights: Edward A. Pesicka, President & CEO,…
BostonGene Partners with Takeda for AI-Driven Immunotherapy Evaluation
BostonGene, a leader in AI-driven molecular and immune profiling solutions, has announced a new research collaboration with Takeda focused on immuno-oncology. This partnership aims to enhance clinical solutions and patient outcomes by pinpointing key molecular drivers and predictive markers of…
Twist Bioscience Reports Q3 2024 Financial Results
Twist Bioscience Corporation (NASDAQ: TWST), known for its high-quality synthetic DNA via its silicon platform, has reported its financial results and business highlights for the third quarter of fiscal 2024, ending June 30, 2024. Financial Performance Business Highlights Emily M.…
Adaptimmune’s TECELRA® Gets FDA Accelerated Approval as First Engineered Cell Therapy for Solid Tumors
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced that the U.S. FDA has granted accelerated approval for TECELRA® (afamitresgene autoleucel) as the first engineered cell therapy for treating solid tumors. This approval is specifically for adults with unresectable or metastatic synovial…
VSee Health and Ava Robotics Team Up for ICU Telepresence Solutions
VSee Health, Inc. (Nasdaq: VSEE), known for its telehealth services that optimize workflows and improve patient care, has partnered with Ava Robotics, a leader in intelligent workplace robots. Together, they will develop telepresence solutions for the inpatient ICU market, including…
Eric Swaim of HealthTrust Wins 40 Under 40 Award
Eric Swaim, VP of Strategic Sourcing at HealthTrust Performance Group, has received Healthcare Purchasing News’ inaugural 40 Under 40 award. This honor highlights outstanding professionals in healthcare who are significantly impacting their organizations. HealthTrust Performance Group, a leader in healthcare…
Desktop Health® Validates Flexcera® Smile Ultra+ Resin for All-on-X Implant Provisionals
Desktop Health, a leading brand in production-grade medical 3D printing from Desktop Metal, Inc. (NYSE: DM), has validated its Flexcera® Smile Ultra+ resin for use in dental implantology, specifically for All-on-X implant provisionals. Flexcera Smile Ultra+ is already FDA (510)k…
Eisai Chooses Medidata’s Clinical Data Studio to Boost Trial Efficiency and Patient Experience
Medidata, a Dassault Systèmes company and a leading provider of clinical trial solutions, has announced that Eisai Incorporated, the U.S. subsidiary of Tokyo-based Eisai Co., Ltd., is among the first to implement the new Medidata Clinical Data Studio. This advanced…